A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup
Akira Kawai(GTx (United States)), Nobuaki Fukasawa(Novartis (Japan)), Taito Esaki(National Hospital Organization Kyushu Cancer Center), Akihiko Matsumine(University of Fukui), Takafumi Ueda(The University of Osaka), Hideshi Sugiura, Michiko Machida(Novartis (Japan)), Nobuhito Araki(Mie University), Toshifumi Ozaki(Okayama University), Takeshi Ishii(Chiba Cancer Center), Hiroaki Hiraga
Cited by 38
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2021|558